Category Archives: Patent Eligible Subject Matter

AAM v. Neapco Part II– Judge Moore’s Dissent – Nothing More = Nevermore?

My first post on this troubling decision is dated August 3rd. If you have not already, please read it before you read this one. It focuses on the two judge majority opinion, that found that a claim to a method … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment

Illumina v. Ariosa – Fed. Cir. Splits a Fine s. 101 Hair

Until I read that another commentator wrote that the split panel decision in Illumina v. Ariosa Diagnostics, Appeal No. 2019-1419 (Fed. Cir., March 17, 2020) struck a hopeful note in the patent eligibility wars, I confess that I had missed … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment

CardioNet v. Infobionics: The Requirement for Improvements in Patent Eligibility

This decision, Appeal No. 2019-1149 (Fed. Cir. April 17th 2020) should have required about 13 pages and could have ended after the first paragraph under Section A. Instead, a split panel required a 23 page majority decision and a 10 … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , | Leave a comment

Solicitor General’s Vanda Brief Deconstructs Mayo

When I was writing my post on INO Therapeutic’s Petition for Cert. on March 16th, I noticed the cite to the “invitation brief in Hikma Pharmaceuticals USA, Inc. v. Vanda Pharmaceuticals Inc., No. 18-817 (U.S. Dec. 6, 2019)(“the brief”). While … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , | Leave a comment